1p8v: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Direct interaction between platelet receptor glycoprotein Ibalpha, (GpIbalpha) and thrombin is required for platelet aggregation and, activation at sites of vascular injury. Abnormal GpIbalpha-thrombin, binding is associated with many pathological conditions,including, occlusive arterial thrombosis and bleeding disorders. The crystal, structure of the GpIbalpha-thrombin complex at 2.6 angstrom resolution, reveals simultaneous interactions of GpIbalpha with exosite I of one, thrombin molecule,and with exosite II of a second thrombin molecule. In, the crystal lattice,the periodic arrangement of GpIbalpha-thrombin, complexes mirrors a scaffold that could serve as a driving force for tight, platelet adhesion. The details of these interactions reconcile, GpIbalpha-thrombin binding modes that are presently, controversial,highlighting two distinct interfaces that are potential, targets for development of novel antithrombotic drugs.
Direct interaction between platelet receptor glycoprotein Ibalpha (GpIbalpha) and thrombin is required for platelet aggregation and activation at sites of vascular injury. Abnormal GpIbalpha-thrombin binding is associated with many pathological conditions,including occlusive arterial thrombosis and bleeding disorders. The crystal structure of the GpIbalpha-thrombin complex at 2.6 angstrom resolution reveals simultaneous interactions of GpIbalpha with exosite I of one thrombin molecule,and with exosite II of a second thrombin molecule. In the crystal lattice,the periodic arrangement of GpIbalpha-thrombin complexes mirrors a scaffold that could serve as a driving force for tight platelet adhesion. The details of these interactions reconcile GpIbalpha-thrombin binding modes that are presently controversial,highlighting two distinct interfaces that are potential targets for development of novel antithrombotic drugs.


==Disease==
==Disease==
Line 17: Line 17:
[[Category: Protein complex]]
[[Category: Protein complex]]
[[Category: Thrombin]]
[[Category: Thrombin]]
[[Category: Dumas, J.J.]]
[[Category: Dumas, J J.]]
[[Category: Kumar, R.]]
[[Category: Kumar, R.]]
[[Category: Mosyak, L.]]
[[Category: Mosyak, L.]]
[[Category: Seehra, J.]]
[[Category: Seehra, J.]]
[[Category: Somers, W.S.]]
[[Category: Somers, W S.]]
[[Category: DFP]]
[[Category: DFP]]
[[Category: MES]]
[[Category: MES]]
Line 28: Line 28:
[[Category: platelet glycoprotein receptor]]
[[Category: platelet glycoprotein receptor]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:39:14 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:26:22 2008''